trending Market Intelligence /marketintelligence/en/news-insights/trending/kuuabfgjf2xeew0l57gn9w2 content esgSubNav
In This List

Gene therapy focused Genprex prices IPO

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Gene therapy focused Genprex prices IPO

Genprex Inc. priced its IPO of 1,280,000 common shares at $5 apiece.

Network 1 Financial Securities Inc. is acting as the sole book-running manager for the offering which is expected to close on April 3.

The Austin, Texas-based company, which is developing a therapy for lung cancer, is listing on Nasdaq under the symbol 'GNPX.'

The IPO's underwriters can buy up to an additional 192,000 shares from the company.